Nutritional Supplement's Effects on Cognition
An Examination Into the Effects of a Nutraceutical Supplement on Cognition, Stress, and Eye and Skin Health in Adults With Self-reported Cognitive Complaints: a Randomised, Double-blind, Placebo-controlled Trial
1 other identifier
interventional
110
1 country
1
Brief Summary
This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 26, 2023
CompletedStudy Start
First participant enrolled
July 5, 2023
CompletedFirst Posted
Study publicly available on registry
July 12, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2024
CompletedJuly 13, 2023
July 1, 2023
6 months
May 26, 2023
July 11, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change in working memory
Determine change in working memory as measured by the Numeric Working Memory Test
Baseline and Week 12
Change in Working memory by Corsi Block tasks
Determine if working memory change by doing Corsi blocks task
Baseline and Week 12
Change in verbal learning and memory
Determine if verbal learning and memory change using total score on Rey Auditory Verbal Learning test trials 1 to 5
Baseline and Week 12
Change in episodic memory
Determine change in episodic memory as measured by Rey Auditory Verbal Learning Test delayed recall and computerized location learning task
Baseline and Week 12
Secondary Outcomes (9)
Change in accuracy of attention
Baseline and Week 12
Change in the Everyday Memory
Baseline, Week 4, Week 8, Week 12
Change in the Perceived Stress score
Baseline, Week 4, Week 8, Week 12
Change in the World Health Organization score
Baseline, Week 4, Week 8, Week 12
Change in oxidative stress marker
Baseline and Week 12
- +4 more secondary outcomes
Other Outcomes (3)
Change in Ocular Surface Disease Index score
Baseline, Week 4, Week 8, Week 12
Change in diastolic blood pressure measurement (safety measure)
Baseline and Week 12
Change in systolic blood pressure measurement (safety measure)
Baseline and Week 12
Study Arms (2)
Active
EXPERIMENTALSoftgel containing: Astaxanthin, Grape Juice Extract, and All Natural Vitamin E
Placebo
PLACEBO COMPARATORSoftgel containing: Olive Oil and Sunflower Lecithin
Interventions
2 softgels per day
Eligibility Criteria
You may qualify if:
- Health Individuals
- Residing in independent living accommodations
- Subjective report of memory or attention problems by answering 'yes' to the following questions: Do you have problems with your memory, attention, or concentration?
- Non-smoker
- Body Mass Index (BMI) between 18-35 kg/m2
- No plan to commence new treatments over the study period
- Understand, willing and able to comply with all study procedures
- Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the study
You may not qualify if:
- Diagnosis of dementia based on the revised National Institute on Aging-Alzheimer's Association (NIA/AA) criteria
- A score below the 5th percentile for age, education, and gender on the Telephone Interview for Cognitive Status (TICS-M)
- Suffering from recently diagnosed or unmanaged medical conditions including but not limited to diabetes, hyper/hypotension, cardiovascular disease, gallbladder disease, autoimmune disease, endocrine disease, or cancer/malignancy
- Diagnosis of a psychiatric disease (other than mild-to moderate depression of anxiety) and/or neurological condition/disease (e.g. Parkinson's, Alzheimer's disease)
- History of paralysis, stroke or seizures or head injury (with loss of consciousness)
- Regular medication intake including but not limited to anticholinergics, acetylcholinesterase inhibiters, or steroid medications.
- Taking vitamins or herbal supplements that are reasonably expected to influence study measures
- In the last 6 month, commenced or changed the dose of nutritional and/or herbal supplements that may impact on treatment outcome
- Alcohol intake greater than 14 standard drinks per week
- Current or 12-month history of illicit drug abuse
- Pregnant women, women who are Brest feeding, or women who intend to fall pregnant
- Any significant surgeries over the last year
- Planned major lifestyle change in the next 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pharmanexlead
- Clinical Research Australiacollaborator
Study Sites (1)
Clinical Research Australia
Duncraig, Western Austrailia, 6023, Australia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adrian Lopresti, MD
Clinical Research Australia
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Softgels with similar appearance
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2023
First Posted
July 12, 2023
Study Start
July 5, 2023
Primary Completion
January 1, 2024
Study Completion
June 1, 2024
Last Updated
July 13, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share
No plan to share individual participant data. Will only report summary data i.e. means by responses to specific variables.